Endocrine-related cancer最新文献

筛选
英文 中文
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. 世界卫生组织垂体神经内分泌肿瘤分类:临床病理评价。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-22 Print Date: 2023-08-01 DOI: 10.1530/ERC-23-0021
Chiara Villa, Bertrand Baussart, Guillaume Assié, Gerald Raverot, Federico Roncaroli
{"title":"The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.","authors":"Chiara Villa, Bertrand Baussart, Guillaume Assié, Gerald Raverot, Federico Roncaroli","doi":"10.1530/ERC-23-0021","DOIUrl":"10.1530/ERC-23-0021","url":null,"abstract":"<p><p>The classification of tumours of the pituitary gland has recently been revised in the 2021 5th edition World Health Organization (WHO) Classification of Central Nervous System Tumours (CNS5) and 2022 5th edition WHO Classification of Endocrine and Neuroendocrine Tumours (ENDO5). This brief review aims to appraise the most relevant changes and updates introduced in the two classifications. A new nomenclature has been introduced in CNS5 and ENDO5 to align adenohypophyseal tumours with the classification framework of neuroendocrine neoplasia. The term pituitary neuroendocrine tumour (PitNET) with subtype information has therefore been adopted and preferred to adenoma. Pituitary carcinoma has been replaced by metastatic PitNET. The ICD-O coding has been changed from benign to malignant in line with NETs from other organs. Histological typing and subtyping based on immunohistochemistry for lineage-restricted pituitary transcription factors are regarded as the cornerstone for accurate classification. Such an approach does not fully reflect the complexity and dynamics of pituitary tumorigenesis and the variability of transcription factors expression. ENDO5 does not support a grading and/or staging system and argues that histological typing and subtyping are more robust than proliferation rate and invasiveness to stratify tumours with low or high risk of recurrence. However, the prognostic and predictive relevance of histotype is not fully validated. Recent studies suggest the existence of clinically relevant molecular subgroups and emphasize the need for a standardized, histo-molecular integrated approach to the diagnosis of PitNETs to further our understanding of their biology and overcome the unsolved issue of grading and/or staging system.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 8","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10052398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. 在常规疾病管理或临终关怀的背景下,为神经内分泌肿瘤患者提供姑息治疗时的实际考虑。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-21 Print Date: 2023-07-01 DOI: 10.1530/ERC-22-0226
Jaydira Del Rivero, Josh Mailman, Michael W Rabow, Jennifer A Chan, Sarah Creed, Hagen F Kennecke, Janice Pasieka, Jennifer Zuar, Simron Singh, Lauren Fishbein
{"title":"Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care.","authors":"Jaydira Del Rivero,&nbsp;Josh Mailman,&nbsp;Michael W Rabow,&nbsp;Jennifer A Chan,&nbsp;Sarah Creed,&nbsp;Hagen F Kennecke,&nbsp;Janice Pasieka,&nbsp;Jennifer Zuar,&nbsp;Simron Singh,&nbsp;Lauren Fishbein","doi":"10.1530/ERC-22-0226","DOIUrl":"10.1530/ERC-22-0226","url":null,"abstract":"<p><p>This serves as a white paper by the North American Neuroendocrine Tumor Society (NANETS) on the practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. The authors involved in the development of this manuscript represent a multidisciplinary team of patient advocacy, palliative care, and hospice care practitioners, endocrinologist, and oncologists who performed a literature review and provided expert opinion on a series of questions often asked by our patients and patient caregivers affected by this disease. We hope this document serves as a starting point for oncologists, palliative care teams, hospice medical teams, insurers, drug manufacturers, caregivers, and patients to have a frank, well-informed discussion of what a patient needs to maximize the quality of life during a routine, disease-directed care as well as at the end-of-life.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 7","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9762616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients. 非裔美国人与高加索人种/民族在肾上腺皮质癌患者中的差异。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-02 Print Date: 2023-07-01 DOI: 10.1530/ERC-22-0249
Andrea Panunzio, Stefano Tappero, Lukas Hohenhorst, Cristina Cano Garcia, Mattia Piccinelli, Francesco Barletta, Zhe Tian, Alessandro Tafuri, Alberto Briganti, Ottavio De Cobelli, Felix K H Chun, Derya Tilki, Carlo Terrone, Fred Saad, Shahrokh F Shariat, Isabelle Bourdeau, Maria Angela Cerruto, Alessandro Antonelli, Pierre I Karakiewicz
{"title":"African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients.","authors":"Andrea Panunzio,&nbsp;Stefano Tappero,&nbsp;Lukas Hohenhorst,&nbsp;Cristina Cano Garcia,&nbsp;Mattia Piccinelli,&nbsp;Francesco Barletta,&nbsp;Zhe Tian,&nbsp;Alessandro Tafuri,&nbsp;Alberto Briganti,&nbsp;Ottavio De Cobelli,&nbsp;Felix K H Chun,&nbsp;Derya Tilki,&nbsp;Carlo Terrone,&nbsp;Fred Saad,&nbsp;Shahrokh F Shariat,&nbsp;Isabelle Bourdeau,&nbsp;Maria Angela Cerruto,&nbsp;Alessandro Antonelli,&nbsp;Pierre I Karakiewicz","doi":"10.1530/ERC-22-0249","DOIUrl":"10.1530/ERC-22-0249","url":null,"abstract":"<p><p>In some primaries, African American race/ethnicity predisposes to higher stage and worse survival. We tested for differences in cancer-specific mortality (CSM) and other-cause mortality (OCM) in patients with adrenocortical carcinoma (ACC) according to African American vs Caucasian race/ethnicity. We hypothesized that African Americans present with higher tumor stage and grade, do not receive the same treatment, and experience worse oncological outcomes than Caucasians. Within Surveillance, Epidemiology, and End Results database, we identified 1016 ACC patients: 123 (12.1%) African Americans vs 893 (87.9%) Caucasians. Propensity score matching (PSM) (age, sex, marital status, grade, T, N, and M stages, and treatment type), Poisson-smoothed cumulative incidence plots, and competing risk regression (CRR) were used. Compared to Caucasians, African Americans were more frequently unmarried (56.9% vs 35.5%, P < 0.001). No clinically meaningful or statistically significant differences were observed for age, grade, T, N, and M stages, as well as treatment type (all P > 0.05). After PSM (1:4), 123 African Americans and 492 Caucasians remained and were included in CRR analysis. In multivariable CRR models, CSM and OCM rates were not different between the two race/ethnicities (hazard ratio: 0.84, P = 0.3). In African Americans, 5-year CSM rates were 31.2% and 75.3% in European Network for the Study of Adrenal Tumors (ENSAT) stages I-II and III-IV, respectively vs 32.9% and 75.4% in Caucasians. Overall 5-year OCM rates were 11.0% vs 10.1% in respectively African Americans and Caucasians. Unlike other primaries, in ACC, African American race/ethnicity is not associated with higher disease stage at initial diagnosis or worse survival.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 7","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9608662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer in Ecuadorian subjects with Laron syndrome (ELS). 厄瓜多尔Laron综合征(ELS)患者的癌症。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-01 DOI: 10.1530/ERC-22-0389
Jaime Guevara-Aguirre, Gabriela Peña, Gabriel Pazmiño, William Acosta, Jannette Saavedra, Daniela Lescano, Alexandra Guevara, Antonio W D Gavilanes
{"title":"Cancer in Ecuadorian subjects with Laron syndrome (ELS).","authors":"Jaime Guevara-Aguirre,&nbsp;Gabriela Peña,&nbsp;Gabriel Pazmiño,&nbsp;William Acosta,&nbsp;Jannette Saavedra,&nbsp;Daniela Lescano,&nbsp;Alexandra Guevara,&nbsp;Antonio W D Gavilanes","doi":"10.1530/ERC-22-0389","DOIUrl":"https://doi.org/10.1530/ERC-22-0389","url":null,"abstract":"<p><p>Meta-analyses from 2018-2022 have shown that obesity increases the risk of various cancers such as acute myeloid lymphoma, chronic myeloid lymphoma, diffuse beta cell lymphoma, Hodgkin's lymphoma, leukemia, multiple myeloma, non-Hodgkin's lymphoma, bladder, breast, cholangiocarcinoma, colorectal, ovarian, esophageal, kidney, liver, prostate, thyroid, and uterus. Contextually, obesity, and its comorbidities, is the largest, most lethal pandemics in the history of mankind; hence, identification of underlying mechanisms is needed to adequately address this global health threat. Herein, we present the metabolic and hormonal mechanisms linked to obesity that might etiologically contribute to neoplasia, including hyperinsulinemia and putative places in the insulin-signaling pathway. Excess insulin, acting as a growth factor, might contribute to tumorigenesis, while abundant ATP and GDP supply the additional energy needed for proliferation of rapidly dividing cells. Our observations in the Ecuadorian cohort of subjects with Laron syndrome (ELS) prove that obesity does not always associate with increased cancer risk. Indeed, despite excess body fat from birth to death, these individuals display a diminished incidence of cancer when compared to their age- and sex-matched relatives. Furthermore, in cell cultures exposed to potent oxidizing agents, addition of ELS serum induces less DNA damage as well as increased apoptosis. ELS individuals have absent growth hormone (GH) counter-regulatory effects in carbohydrate metabolism due to a defective GH receptor. The corresponding biochemical phenotype includes extremely low basal serum concentrations of insulin and insulin-like growth factor-I, lower basal glucose and triglyceride (TG) levels, and diminished glucose, TG, and insulin responses to orally administered glucose or to a mixed meal.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9914441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Talking about sex: erectile dysfunction in the oncology patient. 谈论性:肿瘤患者的勃起功能障碍。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-01 DOI: 10.1530/ERC-22-0401
Marilina Romeo, Giorgia Spaggiari, Chiara Furini, Antonio R M Granata, Angela Toss, Manuela Simoni, Daniele Santi
{"title":"Talking about sex: erectile dysfunction in the oncology patient.","authors":"Marilina Romeo,&nbsp;Giorgia Spaggiari,&nbsp;Chiara Furini,&nbsp;Antonio R M Granata,&nbsp;Angela Toss,&nbsp;Manuela Simoni,&nbsp;Daniele Santi","doi":"10.1530/ERC-22-0401","DOIUrl":"https://doi.org/10.1530/ERC-22-0401","url":null,"abstract":"<p><p>Cancer-related diagnosis and treatments can profoundly affect every aspect of an individual's life. The negative impact on the sexual sphere can manifest with onset or worsening of the most frequent male form of sexual dysfunction, that is the erectile dysfunction (ED), with an estimated incidence ranging from 40 to 100% in patients living with cancer. Cancer and ED are strictly related for many reasons. First, the psychological distress, the so-called 'Damocles syndrome', afflicting cancer patients contributes to ED onset. Second, all cancer therapies can variably lead to sexual dysfunction, even more than the disease itself, having both direct or indirect effects on sexual life. Indeed, alongside pelvic surgery and treatments directly impairing the hypothalamus-pituitary-gonadal axis, the altered personal-body-image frequently experienced by people living with cancer may represent a source of distress contributing to sexual dysfunction. It is undeniable that sexual issues are currently neglected or at least under-considered in the oncological setting, mainly due to the subjective lack of preparation experienced by healthcare professionals and to scant information provided to oncological patients on this topic. To overcome these management problems, a new multidisciplinary medical branch called 'oncosexology' was set up. The aim of this review is to comprehensively evaluate ED as an oncology-related morbidity, giving new light to sexual dysfunction management in the oncological setting.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms. 早发性神经内分泌肿瘤患者的种系致病变异。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-01 DOI: 10.1530/ERC-22-0258
Rachel Pimenta Riechelmann, Mauro D Donadio, Victor Hugo F de Jesus, Nathalia de Angelis de Carvalho, Karina Miranda Santiago, Milton J Barros, Laura Lopes, Gabriel Oliveira Dos Santos, Maria Nirvana Formiga, Dirce Maria Carraro, Giovana Tardin Torrezan
{"title":"Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms.","authors":"Rachel Pimenta Riechelmann,&nbsp;Mauro D Donadio,&nbsp;Victor Hugo F de Jesus,&nbsp;Nathalia de Angelis de Carvalho,&nbsp;Karina Miranda Santiago,&nbsp;Milton J Barros,&nbsp;Laura Lopes,&nbsp;Gabriel Oliveira Dos Santos,&nbsp;Maria Nirvana Formiga,&nbsp;Dirce Maria Carraro,&nbsp;Giovana Tardin Torrezan","doi":"10.1530/ERC-22-0258","DOIUrl":"https://doi.org/10.1530/ERC-22-0258","url":null,"abstract":"<p><p>Neuroendocrine neoplasms (NENs) are a rare group of cancers with heterogeneous behaviour and mostly of unknown aetiology. Excluding some infrequent hereditary cancer syndromes, the extent and clinical significance of mutations in other cancer predisposing genes (CPGs) are not known. We aimed to investigate the frequency of pathogenic and likely germline pathogenic variants (GPVs) in known CPGs in young adults with NEN and the clinical and molecular characteristics of these patients. We recruited 108 patients with lung or digestive NEN diagnosed between 18 and 50 years and performed targeted sequencing of 113 CPGs on germline DNA. For some patients, tumour features such as loss of heterozygosity (LOH), tumour mutation burden and microsatellite instability were evaluated. GPVs were detected in 17 patients (15.7%). Median age, sex, stage at diagnosis, family history of NENs or any personal history of neoplasm were similar between patients with or without GPVs. GPV carriers had more gastric (P = 0.084), functioning NEN (P = 0.041), positive family history of cancer (P = 0.015) and exclusively well-differentiated histology. Genes affected were mostly involved in DNA repair (CHEK2, ERCC2, ERCC3, XPC, MSH6, POLE and SLX4), with most GPVs found in MUTYH (four cases). LOH was performed in eight tumours and detected only in an SLX4-positive case. Overall, our findings indicate a role of inherited genetic alterations, particularly in DNA repair genes, in NEN carcinogenesis in young adults. These patients more often had a family history of cancer and functioning NENs.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9547432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Metabolomics in paraganglioma: applications and perspectives from genetics to therapy. 代谢组学在副神经节瘤中的应用:从遗传学到治疗的观点。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-01 DOI: 10.1530/ERC-22-0376
Susan Richter, Timothy J Garrett, Nicole Bechmann, Roderick J Clifton-Bligh, Hans K Ghayee
{"title":"Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.","authors":"Susan Richter,&nbsp;Timothy J Garrett,&nbsp;Nicole Bechmann,&nbsp;Roderick J Clifton-Bligh,&nbsp;Hans K Ghayee","doi":"10.1530/ERC-22-0376","DOIUrl":"https://doi.org/10.1530/ERC-22-0376","url":null,"abstract":"<p><p>Metabolites represent the highest layer of biological information. Their diverse chemical nature enables networks of chemical reactions that are critical for maintaining life by providing energy and building blocks. Quantification by targeted and untargeted analytical methods using either mass spectrometry or nuclear magnetic resonance spectroscopy has been applied to pheochromocytoma/paraganglioma (PPGL) with the long-term goal to improve diagnosis and therapy. PPGLs have unique features that provide useful biomarkers and clues for targeted treatments. First, high production rates of catecholamines and metanephrines allow for specific and sensitive detection of the disease in plasma or urine. Secondly, PPGLs are associated with heritable pathogenic variants (PVs) in around 40% of cases, many of which occur in genes encoding enzymes, such as succinate dehydrogenase (SDH) and fumarate hydratase (FH). These genetic aberrations lead to the overproduction of oncometabolites succinate or fumarate, respectively, and are detectable in tumors and blood. Such metabolic dysregulation can be exploited diagnostically, with the aim to ensure appropriate interpretation of gene variants, especially those with unknown significance, and facilitate early tumor detection through regular patient follow-up. Furthermore, SDHx and FH PV alter cellular pathways, including DNA hypermethylation, hypoxia signaling, redox homeostasis, DNA repair, calcium signaling, kinase cascades, and central carbon metabolism. Pharmacological interventions targeted toward such features have the potential to uncover treatments against metastatic PPGL, around 50% of which are associated with germline PV in SDHx. With the availability of omics technologies for all layers of biological information, personalized diagnostics and treatment is in close reach.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9562246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity. 再激活的甲状腺激素受体β可减弱间变性甲状腺癌(ATC)干细胞的活性。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-06-01 DOI: 10.1530/ERC-22-0306
Xuguang Zhu, Li Zhao, Woo Kyung Lee Doolittle, Sheue-Yann Cheng
{"title":"Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.","authors":"Xuguang Zhu,&nbsp;Li Zhao,&nbsp;Woo Kyung Lee Doolittle,&nbsp;Sheue-Yann Cheng","doi":"10.1530/ERC-22-0306","DOIUrl":"https://doi.org/10.1530/ERC-22-0306","url":null,"abstract":"<p><p>Anaplastic thyroid cancer (ATC) is one of the most aggressive solid cancers in humans, with limited treatment options. Recent studies suggest that cancer stem cell (CSC) activity contributes to therapeutic resistance and recurrence of ATC. We show that the expression of the endogenous thyroid hormone receptor β gene (THRB) is silenced in ATC and demonstrate that the exogenously expressed TRβ suppresses CSC activity. Decitabine is one of the demethylation agents to treat myelodysplastic syndrome and acute myeloid leukemia patients and is currently in clinical trials for hematopoietic malignancies and solid tumors. We aim to show that the re-expression of the endogenous THRB gene by decitabine can attenuate CSC activity to block ATC tumor growth. We treated ATC cell lines derived from human ATC tumors (11T and 16T cells) with decitabine and evaluated the effects of the reactivated endogenous TRβ on CSC activity in vitro and in vivo xenograft models. We found that treatment of 11T and 16T cells with decitabine reactivated the expression of endogenous TRβ, as evidenced by western blot and immunohistochemical analyses. The expressed TRβ inhibited cell proliferation by arresting cells at the S phase, increased apoptotic cell death by upregulation of cleaved caspase-3, and markedly suppressed the expression of CSC regulators, including cMYC, ALDH, SOX2, CD44, and β-catenin. Decitabine also inhibited xenograft tumor growth by suppressing CSC activity, inhibiting cancer cell proliferation, and increasing apoptosis. Our findings suggest that re-expression of the endogenous TRβ is a novel therapeutic approach for ATC via suppression of CSC activity.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354538/pdf/nihms-1889817.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9918846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulinomatosis: new aspects. 胰岛素瘤病:新方面。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-05-16 Print Date: 2023-06-01 DOI: 10.1530/ERC-22-0327
Emanuel Christ, Donato Iacovazzo, Marta Korbonits, Aurel Perren
{"title":"Insulinomatosis: new aspects.","authors":"Emanuel Christ,&nbsp;Donato Iacovazzo,&nbsp;Marta Korbonits,&nbsp;Aurel Perren","doi":"10.1530/ERC-22-0327","DOIUrl":"10.1530/ERC-22-0327","url":null,"abstract":"<p><p>Endogenous hyperinsulinemic hypoglycemia (EHH) is a rare condition with an incidence of approximately 4-6 per million person-years and comprises a group of disorders causing hyperinsulinemic hypoglycemia without exogenous administration of insulin or its secretagogues. In adults, most cases (approximately 90%) are secondary to a single insulinoma. Other causes include insulinoma in the context of multiple endocrine neoplasia type 1 (approximately 5% of cases) and non-insulinoma pancreatogenous hypoglycemia syndrome, which is estimated to account for 0.5-5% of all cases. Recently, an entity called insulinomatosis has been described as a novel cause of EHH in adults. The characteristic feature of insulinomatosis is the synchronous or metachronous occurrence of multiple pancreatic neuroendocrine tumors expressing exclusively insulin. While most cases arise sporadically, there is recent evidence that autosomal dominant inheritance of mutations in the v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) gene can cause a familial form of insulinomatosis. In these families, EHH is paradoxically associated with the occurrence of diabetes mellitus within the same family. This review summarizes the current clinical, biochemical, imaging and genetic knowledge of this disease.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis. 小肠神经内分泌肿瘤与肠系膜纤维化的蛋白质组学分析。
IF 3.9 2区 医学
Endocrine-related cancer Pub Date : 2023-05-11 Print Date: 2023-06-01 DOI: 10.1530/ERC-22-0237
Anela Blazevic, Anand M Iyer, Marie-Louise F Van Velthuysen, Johannes Hofland, Gaston J H Franssen, Richard A Feelders, Marina Zajec, Theo M Luider, Wouter W de Herder, Leo J Hofland
{"title":"Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis.","authors":"Anela Blazevic,&nbsp;Anand M Iyer,&nbsp;Marie-Louise F Van Velthuysen,&nbsp;Johannes Hofland,&nbsp;Gaston J H Franssen,&nbsp;Richard A Feelders,&nbsp;Marina Zajec,&nbsp;Theo M Luider,&nbsp;Wouter W de Herder,&nbsp;Leo J Hofland","doi":"10.1530/ERC-22-0237","DOIUrl":"10.1530/ERC-22-0237","url":null,"abstract":"<p><p>Mesenteric metastases in small intestinal neuroendocrine tumors (SI-NETs) are associated with mesenteric fibrosis (MF) in a proportion of patients. MF can induce severe abdominal complications, and an effective preventive treatment is lacking. To elucidate possible novel therapeutic targets, we performed a proteomics-based analysis of MF. The tumor cell and stromal compartment of primary tumors and paired mesenteric metastases of SI-NET patients with MF (n = 6) and without MF (n = 6) was analyzed by liquid chromatography-mass spectrometry-based proteomics. Analysis of differential protein abundance was performed. Collagen alpha-1(XII) (COL12A1) and complement component C9 (C9) expression was evaluated by immunohistochemistry (IHC) in mesenteric metastases. A total of 2988 proteins were identified. Unsupervised hierarchical clustering showed close clustering of paired primary and mesenteric tumor cell samples. Comparing MF to non-MF samples, we detected differentially protein abundance solely in the mesenteric metastasis stroma group. There was no differential abundance of proteins in tumor cell samples or primary tumor stroma samples. Analysis of the differentially abundant proteins (n = 36) revealed higher abundance in MF samples of C9, various collagens and proteoglycans associated with profibrotic extracellular matrix dysregulation and signaling pathways. Proteins involved in fatty acid oxidation showed a lower abundance. COL12A1 and C9 were confirmed by IHC to have significantly higher expression in MF mesenteric metastases compared to non-MF. In conclusion, proteome profiles of SI-NETs with and without MF differ primarily in the stromal compartment of mesenteric metastases. Analysis of differentially abundant proteins revealed possible new signaling pathways involved in MF development. In conclusion, proteome profiles of SI-NETs with and without MF differ primarily in the stromal compartment of mesenteric metastases. Analysis of differentially abundant proteins revealed possible new signaling pathways involved in MF development.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":3.9,"publicationDate":"2023-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9543282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信